Zydus Cadila receives final approval from USFDA for Allopurinol Tablets

16 Oct 2017 Evaluate

Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Allopurinol Tablets USP, 100 mg and 300 mg. The drug is indicated in the management of patients with gout and patients with cancer who are receiving therapy that causes elevations of serum and urinary uric acid levels. It will be manufactured at the group’s formulations manufacturing facility at Baddi.

The sales of Allopurinol Tablets USP are estimated at $141.2 million. The group now has more than 160 approvals and has so far filed over 300 AND As since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

907.45 -2.55 (-0.28%)
17-Feb-2026 12:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.35
Dr. Reddys Lab 1269.85
Cipla 1346.30
Zydus Lifesciences 907.45
Lupin 2248.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×